**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 26717**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

**Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU *in vivo***

Xie Q *et al.* Anticancer effect of 5-FU and rAd-p53

Qi Xie, Min-Yi Wu, Ding-Xuan Zhang, Yi-Ming Yang , Bao-Shuai Wang, Jing Zhang, Jin Xu, Wei-De Zhong, Jia-ni Hu

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Qi Xie**, **Min-Yi Wu,** **Ding-Xuan Zhang, Yi-Ming Yang, Bao-Shuai Wang,** Medical Imaging Department, Nansha Central Hospital, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 511457, Guangdong Province, China

**Jing Zhang,** Department of Pathology, Cancer Center, Sun-Yat Sen University, Guangzhou 510080, Guangdong Province, China

**Jin Xu,** Department of Pathology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong Province, China

**Wei-De Zhong**, Clinical Molecular Medicine and Molecular Diagnostics Laboratory, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong Province, China

**Jia-ni Hu,** Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States

**Author contributions:** Xie Q designed the study; Wu MY, Zhang DX and Yang YM performed the research; Zhang J and Xu J collected and analyzed the data; Wang BS performed MRI; Zhong WD conducted the statistical analysis; Xie Q and Zhang DX wrote the manuscript; and Hu JN revised the manuscript.

**Supported by** Natural Science Foundation of Guangdong, No. 2015A030313732.

**Institutional review board statement:** The study was reviewed and approved by the Experimental Animal Center of Sun Yat-sen University and Guangzhou Medical University respectively.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Yat-sen University and Guangzhou Medical University.

**Conflict-of-interest statement:** To the best of our knowledge, no conflict of interest exists.

**Data sharing statement**: Technical appendix, statistical code, and dataset available from the corresponding author at xieqi8@yeah.net. No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC Y-NC 4.0) license,which permits others to distribute, remix, adapt, build upon this work noncommercially,and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Qi Xie, MD,** Medical Imaging Department, Nansha Central Hospital, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 511457, Guangdong Province, China. xieqi8@yeah.net

**Telephone:** +86-20-22903628

**Fax:** +86-20-22903699

**Received:** April 23, 2016

**Peer-review started:** April 23, 2016

**First decision:** May 27, 2016

**Revised:** June 11, 2016

**Accepted:** July 6, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To investigate the anticancer effect of a recombinant adenovirus-mediated p53 (rAd-p53) combined with 5-fluorouracil (5-FU) in human colon cancer resistant to 5-FU *in vivo* and the mechanism of rAd-p53 in reversal of 5-FU resistance .

**METHODS**: Nude mice bearing human colon cancer SW480/5-FU (5-FU resistant) were randomly assigned to four groups (*n* = 25): control group, 5-FU group, rAd-p53 group, and the rAd-p53+5-FU group. At 24 h, 48 h, 72 h, 120 h and 168 h after treatment, 5 mice were randomly selected from each group and sacrificed using an overdose of anesthetics. The tumors were removed and the protein expressions of p53, protein kinase C (PKC), permeability-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (Western blot) and apoptosis (TUNEL) were determined.

**RESULTS**: The area ratios of tumor cell apoptosis were larger in the rAd/p53+5-FU group than that in control,5-Fu and rAd/p53 group (*P <* 0.05), and were larger in the rAd/p53 group than that of control group(*P <* 0.05）and 5-FU group more than 48h (*P <* 0.05）.The P53 expression was more in the rAd/p53 and the rAd/p53+5-FU group than that of control and 5-FU group (*P <* 0.05), and were higher in rAd/p53+5-FU group tnan that of rAd/p53 group(*P <* 0.05).The overexpression of PKC, P-gp and MRP1 were observed in 5-FU and control group. In the rAd/p53+5-FU group,the expression of P-gp and MRP1 were lower that of control and 5-FU group (*P <* 0.05), the expression of PKC were lower that of control ,5-FU and rAd/p53 group more than 48h(*P <* 0.05). In rAd/p53 group,the expression of P-gp and MRP1 were lower that of control and 5-FU group more than 48h(*P <* 0.05)， the expression of PKC were lower that of control and 5-FU group more than 120h (*P <* 0.05).

**CONCLUSION:** 5-FU combined with rAd-p53 has a synergistic anticancer effect in SW480/5-Fu(5-Fu resistance) **，**which contribute to reverse 5-Fu resistance **.**

**Key words:** Human colon cancer; Multidrug resistance; 5-Fluorouracil; rAd-p53；Xenografts in nude mice

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights

reserved.

**Core tip**: To observe anticancer action of rAd-p53 combined with 5-FU in human colon cancer of resistance to 5-FU *in vivo* to investigate the potential and mechanism of rAd-p53 in the reversal resistance to 5-FU in human colon cancer.Our previous results revealed thatexogenous wild-type p53 gene from rAd-p53 can decrease expression of PKC, P- gp, MRP1 in SW480/5-Fu(5-Fu resistance) and promote apoptosis of tumor cell, which contribute to reverse 5-Fu resistance *in vivo*. 5-Fu can increase the expression of exogenous wild-type p53, so 5-FU combined with rAd-p53 has a synergistic anticancer effect for colon cancer of 5-Fu resistance *in vivo*.

Xie Q, Wu MY, Zhang DX, Yang YM, Wang BS, Zhang J, Xu J, Zhong WD, Hu JN*.*Synergistic anticancer action of exogenous wild p53 gene combined with 5-FU in human colon cancer of resistance to 5-FU *in vivo*. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common gastrointestinal cancers. In 2013, there were 1.6 million incident cases of CRC worldwide, with 56% occurring in developing countries and 44% in developed countries, which caused 771000 deaths[1]. Most patients are usually at an advanced stage at the time of diagnosis.

To date, 5-fluorouracil (5-FU) remains a widely used chemotherapeutic drug in the treatment of advanced CRC; however, response rates are only 10% to 15% due to severe side effects and resistance[2]. The anticancer efficacy of 5-FU is thought to be partly attributed to its ability to induce p53-dependent cell growth arrest and apoptosis; consequently, mutations or deletions of p53 can cause cells to become resistant to 5-FU[3–6]. Therefore, overcoming 5-FU resistance caused by mutations or deletions of p53 will be a key issue in the design of more effective individualized therapeutic strategies.

Gene replacement therapy for a mutated p53 gene using a recombinant adenovirus-mediated p53 (rAd-p53) gene reportedly increases apoptosis after administration[7-12]. Our previous results revealed that exogenous wild-type p53 (wt-p53) from rAd-p53 increased tumor necrosis in human colon cancer SW480 (5-FU responsive) harboring mutant p53, and 5-FU combined with rAd-p53 had a synergistic anticancer effect *in vivo*[13]. Therefore, rAd-p53 may contribute to the reversal of resistance to 5-FU in colon cancer.

The present study determined the early therapeutic effectiveness of rAd-p53 alone or in combination with 5-FU for the treatment of human colon cancer SW480/5-FU (5-FU resistant) in a nude mouse model. The potential and mechanism of rAd-p53 in the reversal of resistance to 5-FU in human colon cancer *in vivo* was also investigated.

**MATERIALS AND METHODS**

The present study strictly complied with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Sun Yat-Sen University (2011-0702) and Guangzhou Medical University, Guangzhou, China.

***Cell culture***

The human colon cancer cell line SW480 was purchased from the Cell Bank of Sun Yat-Sen University. The cells were cultured in RPMI 1640 with 10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL streptomycin, and grown at 37 °C in a 5% CO2 humidified atmosphere. 5-FU resistant SW480 (SW480/5-FU) cells were generated by continuous exposure to increasing concentrations of 5-FU for more than 5 months. SW480/5-FU cells were able to survive in 6 μg/mL of 5-FU. The IC50 of 5-FU, based on the results of a [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT)] assay, was 23.593 μg/mL for parental cells (SW480) and 140.642 μg/mL for resistant cells (SW480/5-FU). The resistance index (RI) was 5.93. The IC50 of 5-FU in SW480 and SW480/5-FU cells was assayed with [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT)].

***Animal model***

BALB/c nude mice were purchased from the Animal Center of Sun Yat-sen University. A total of 100 four week-old BALB/c nude mice weighing 16–18 g regardless of gender were subcutaneously implanted with SW480/5-FU tissues in the rear flank to generate xenograft models as described previously[13,14]. All surgical procedures were performed under anesthesia induced by chloral hydrate (4.5% chloral hydrate, 2 mL/100 g body weight, intraperitoneal injection), and all efforts were made to minimize suffering. Mice were fed in a specific pathogen-free (SPF) laboratory. One month after implantation, the mice were randomly assigned to four groups (25 per group): control group (medical saline), 5-FU group, rAd-p53 group (Gendicine, Sibiono GeneTech Co., Ltd, Shenzhen, China), and the rAd-p53+5-FU group. The above-mentioned therapeutic agents were administered by intratumoral injection. The dose of rAd-p53 administered was 1 × 107 VIP/mm3 tumor for each group. The dose of 5-FU was 25 mg for tumors 0.5–0.9 cm, 50 mg for tumors 1.0–1.4 cm, and 75 mg for tumors more than 1.5 cm[13].

***Assessment of tumor response***

At 24, 48, 72, 120, and 168 h after treatment, 5 mice were randomly selected from each group and euthanized with an overdose of anesthetics. The tumors were removed and divided into equal halves. One half was immediately frozen at −30°C for Western blot analysis. The other half was fixed in phosphate-buffered saline (pH 7.3) containing 4% formaldehyde and 0.2% glutaraldehyde, embedded in paraffin, and sectioned for TUNEL assay.

***Measurement of apoptosis***

Pathological sections were stained using the TUNEL apoptosis *in situ* detection reagent kit (Keygen, Nanjing, China) according to the manufacturer’s instructions. The area ratio of tumor cell apoptosis was calculated as the percentage of positively stained cell nuclei (dark brown) at 100 × magnification The average of the evaluations by the pathologists (Zhang & Xu) was used for analysis.

***Western blot analysis***

Western blot analysis was used to detect the protein expression of p53, PKC, P-gp and MPR1 as described in the instruction manual (Phototope ® -HRP Western blot kit, Cell Signaling Technology company, United States). Cell extracts were obtained from frozen tumor tissues (-30 ℃). Immunoblot analysis was performed using anti-p53 monoclonal antibodies (Santa Cruz Biotech, United States), anti-PKC and MDR1 and MRP1 monoclonal antibodies (Santa Cruz Biotech, United States). Subsequent protein detection was performed using an enhanced chemiluminescence (ECL) detection system (Hitachi, Japan).

The band intensities (IOD) of protein expression stated above were scanned into the computer and analyzed with Image Pro Plus 6.0 software. The relative IOD (RIOD) of protein expression was calculated as the IOD of the protein in the control group and therapeutic groups at each time point divided by the corresponding IOD of GAPDH (internal control).

***Statistical analysis***

The SPSS 13.1 statistical package (SPSS, Chicago, United States) was used for all calculations. The tumor responses of the whole samples (ANOVA repeated data) and between groups (SNK test) were compared, and the correlations between parameters were evaluated with Pearson's correlation at a significance level of 0.05. Data are presented as mean ± SD of a representative of at least three independently performed experiments.

**RESULTS**

***Tumor cell IC50***

The IC50 of 5-FU based on the results of the MTT assay was 23.593 μg/mL for parental cells (SW480) and 140.642 μg/mL for resistant cells (SW480/5-FU). The resistance index (RI) was 5.93.

***Tumor cell apoptosis***

Tumor cell apoptosis was detected in sections from the 5-FU group and control group at the observed time points (Figure 1), however, there were no significant differences in tumor cell apoptosis between the two groups (SNK test, *P >* 0.05, Table 1).

The area ratio of tumor cell apoptosis in the rAd-p53+5-FU group was significantly larger than that in the control group, 5-FU group and the rAd-p53 group (SNK test, *P <* 0.05, Table 1). The area ratio of tumor cell apoptosis in the rAd-p53 group was significantly larger than that in the control group (SNK test, *P <* 0.05). After > 48 h treatment, the area ratio of tumor cell apoptosis in the rAd-p53 group was significantly larger than that in the 5-FU group (SNK test, *P <* 0.05).

The area ratio of tumor cell apoptosis in the rAd-p53 group and the rAd-p53+5-FU group tended to increase with time (ANOVA, *P <* 0.05).

***Protein expression***

**P53 expression:** P53 protein showed weak expression in the 5-FU group and control group at the observed time points (Figure 2A). There were no significant differences in the RIOD of p53 expression between the two groups (SNK test, *P >* 0.05, Table 2). P53 expression level in the rAd-p53 and the rAd-p53+5-FU group was higher than that in the control and 5-FU groups (SNK test, *P <* 0.05) and increased in a time-dependent manner (ANOVA, *P <* 0.05, Table 2), with peak expression at 120 h. P53 expression in the rAd-p53+5-FU group was significantly higher than that in the rAd-p53 group (SNK test, *P <* 0.05, Table 2).

**PKC, P-gp and MRP1 expression:** Overexpression of PKC, P-gp and MRP1 was observed in the 5-FU group and control group (Figure 2B-D). There were no significant differences in the RIOD of the expression of these proteins between the two groups (SNK test, *P >* 0.05, Tables 3-5).

At the observed time points, the expression of PKC, P-gp and MRP1 in the rAd/p53+5-FU group gradually decreased in a time-dependent manner (ANOVA, *P <* 0.05, Tables 3-5). The expression of P-gp and MRP1 was significantly lower than that in the control group and 5-FU group (SNK test, *P <* 0.05). More than 48 h after treatment, the expression of PKC in the rAd-p53+5-FU group was significantly lower than that in the control group, 5-FU group and rAd-p53 group.

In the rAd-p53 group, the expression of P-gp and MRP1 was significantly lower than that in the control group and 5-FU group > 48 h after treatment (SNK test, *P <* 0.05). The expression of PKC was significantly lower than that in the control group and 5-FU group > 120 h after treatment (SNK test, *P <* 0.05).

***Pearson's correlation test***

The RIOD of p53 expression was positively correlated with the area ratio of tumor cell apoptosis (correlation coefficient and *P* value were 0.545 and 0.000, respectively).

The RIOD of PKC, P-gp and MRP1 expression was negatively correlated with the area ratio of tumor cell apoptosis (correlation coefficients were -0.322, 0.012 and -0.335 and *P* values were 0.009, -0.541 and 0.000, respectively).

The RIOD of p53 expression and the RIOD of PKC, P-gp and MRP1 expression showed a negative correlation (correlation coefficients were -0.366, 0.004 and -0.406 and *P* values were 0.001, -0.488 and 0.000, respectively).

**DISCUSSION**

5-FU is still widely used as a major anticancer drug in the treatment of colon cancer[3]. However, a major impediment to the success of colon cancer chemotherapy is the development of cancer variants exhibiting multidrug resistance (MDR)[2-6,15,16].

MDR usually presents as cross-resistance to multiple chemotherapeutic drugs with different structures[16,17]. Anti-cancer drug resistance in colon cancer cells can be caused by various factors, including alterations in drug influx and efflux, enhancement of drug inactivation and mutation of the drug target induced by various proteins[18-21]. To date, multiple factors have been reported to lead to resistance to chemotherapeutic drugs[16-23]. P-gp, PKC and multidrug resistance-associated proteins (MRPs) contribute to chemotherapy resistance[17-23]. In our previous studies, overexpression of P-gp, PKC and MRP1 was observed in human colon cancer SW480/5-FU cells (5-FU resistant) and weak expression of these proteins was seen in parental human colon cancer SW480 cells (5-FU response)[14].

Various mechanisms contribute to MDR, including the overexpression of drug efflux pumps (pump resistance) and the upregulation of cellular antiapoptotic defense systems (non-pump resistance)[23,24]. P-gp encoded by the MDR1 gene and MRPs belong to the ATP-binding cassette (ABC) superfamily. These transporter proteins (responsible for pump resistance) mediate the efflux of drugs in the MDR spectrum, such as anthracyclines, out of cells, thus reducing drug efficacy[24]. Generally, there are two approaches used to reverse ABC superfamily-mediated MDR: blocking its drug-pump function and inhibiting its expression[25-27].

PKC is one of the signaling enzymes which is positively regulated by reactive oxygen species (ROS) and plays a crucial role in a variety of pathophysiological states including tumor progression. PKC contains multiple cysteine residues which can be oxidatively activated by ROS[28,29]. PKC represents a family of serine/threonine kinases that are involved in the regulation of cell growth, cell death and stress responsiveness[30]. Generally, the PKCs are classified into three subfamilies based on their structural and activation characteristics: the conventional or classic (α, βI, βII, and γ), the novel or non-classic (δ, ε, η and θ), and the atypical PKC isoenzymes (ζ, ι and λ)[30]. Different PKC isoenzymes may exert similar or opposite cellular effects by differential coupling of signaling pathways[31]. Cancer cells survive by evading apoptosis or promoting proliferation, invasion and metastasis. PKC may act as a downstream effector of the signaling protein phosphatidylinositol 3-kinase (PI3K). The PI3K-mediated signaling cascade regulates cell proliferation, cell survival, differentiation and apoptosis[32-34]. Phosphorylation of the regulatory subunit p85a is linked to increased survival of cancer cells. The p85 subunit regulates the catalytic subunit p110 by stabilization and inactivation of its kinase activity in the basal state as well as by recruitment of PI3K to phospho-tyrosine residues of the activated receptors[34,35].

PKCα and PKCβ may promote ABCB1 function by phosphorylation[18,33,34]. Notably, the effects of PKC signaling on ABCB1 phosphorylation and function appear to be cell type-dependent. In ovarian carcinoma cells, antisense oligomers directed against PKCα and PKCβ reversed ABCB1-mediated drug resistance[36]. In contrast, PKCβ was not detectable in some reports, and siRNAs targeting PKCα interfered with PKC signaling, but not with ABCB1 function[18]. Moreover, p53 was shown to suppress PKCα-mediated ABCB1 activation in leiomyosarcoma, fibrosarcoma, and osteosarcoma cells[18,34].

Mutations or deletions of suppressor gene p53 are the most common genetic abnormalities that occur during cancerogenesis in the majority of human neoplasms. P53 gene, localized on the short arm of chromosome 17 (17p13), encodes nucleic phosphoproteins, and affects several cell functions (induction of many genes, regulation of the cell cycle and apoptosis control)[37]. Under the condition of p53 gene mutation, cancer cells remain intact and survive[38].

Evasion from chemotherapy-induced apoptosis due to p53 loss strongly contributes to drug resistance[3-6,16,38]. Wild-type p53 is a key tumor suppressor in preventing tumorigenesis and cancer progression; however, mutant p53, detected in over 50% of all human tumors and in approximately 70% of colorectal cancers[39-43], promotes tumor progression and resistance to therapies[3-6,38,44], and such mutants have become the most common prognostic indicators for both tumor recurrence and cancer death[40,43,45,46]. Prevention of p53 mutation to restore wild-type p53 activity is an attractive anticancer therapy to reverse 5-FU resistance in colon cancer.

Infection with Ad-p53 can significantly downregulate MDR1 transcription and P-gp expression in breast cancer cell lines and reverse resistance to adriamycin[47]. Treatment with rAd-p53 alone, Oxaliplatin alone or combined treatment led to a decrease in Bcl-2 expression and an increase in Bax expression in gastric cancer cells, and induced apoptosis of gastric cancer cells, which was accompanied by increased expression of caspase-3[12]. Therefore, rAd-p53 may enhance the sensitivity of gastric cancer cells to chemotherapy by promoting apoptosis. In the present study, exogenous wild-type p53 gene from rAd-p53 decreased the expression of PKC, P-gp, and MRP1 and promoted apoptosis of colon carcinoma cells in nude mice implanted with human colon carcinoma SW480/5-FU (5-FU resistant), which contributed to the reversal of 5-FU resistance.

The antimetabolite, 5-FU, is an analogue of uracil with a fluorine atom at the C5 position of the pyrimidine ring. 5-FU is converted in cells to different active metabolites, including fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP). These metabolites have been implicated in both global RNA metabolism due to incorporation of the ribonucleotide FUMP into RNA, and DNA metabolism due to thymidylate synthase (TS) inhibition or direct incorporation of FdUMP into DNA, leading to a wide range of biological effects which can act as triggers for apoptotic cell death[3-4,15-16]. Therefore, 5-FU can be regarded as a genotoxic agent.

P53 protein in the production of wild-type p53 expression plays a key role in cell cycle regulation and in the cellular response to cytotoxic stress and DNA damage[48-51]. P53 protein is maintained at low levels by MDM2, an E3-ligase that binds p53 and promotes its degradation[52-54]. DNA damage and other stresses including gamma and UV irradiation, chemotherapeutic agents, hypoxia, heat, or alterations in intracellular nucleotide pools disrupt p53-MDM2 binding, causing p53 levels to increase[49-51,55]. Wild-type p53 is induced in response to a host of genotoxic and environmental stresses, a host of target genes are then transcriptionally activated, including p21, GADD45, Bax, and Bcl-2. Induction of p21, in turn, leads to cell cycle arrest at both G1 and G2 checkpoints. This function is thought to be essential in preserving the integrity of the cellular genome in response to treatment with cytotoxic agents. In addition to mediating cell cycle arrest, p53 is a potent inducer of apoptosis and programmed cell death[49-51].

Increased p53 protein in response to genotoxic stress also occurs in cancer cells[56-59]. Treatment of human colon cancer RKO cells and tetraploid cancer cells with 5-FU resulted in a significant increase in the levels of the endogenous p53 protein family *in vitro* and enhanced tumor suppression[59]. The p53 protein family form an interacting network of proteins[60]. Cancer cell responses to 5-FU treatment are determined by the total activity of the entire p53 family rather than p53 alone[60]. Suppressor p53 is one of the molecular targets of 5-FU. With regard to 5-FU, translational regulation is an important process for controlling endogenous p53 expression[59-61]. Our previous study demonstrated that **t**he expression of exogenous wild-type p53 gene in colon cancer cells in nude mice bearing human colon carcinoma SW480 (5-FU response) treated with rAd-P53+5-FU was significantly higher than that with rAd-P53 alone, and tumor necrosis was positively correlated with p53 expression *in vivo*[13]. 5-FU also increased the anticancer effect of rAd/p53 *in vivo*.

In the present study, p53 expression in colon cancer SW480/5-FU in the rAd/p53 group and rAd-p53+5-FU group was higher than in the control and 5-FU group and increased in a time-dependent manner. P53 expression in the rAd-p53+5-FU group was significantly higher than in the rAd-p53 group. These results suggest that 5-FU increased **t**he expression of exogenous wild-type p53 gene in colon cancer (resistant to 5-FU) *in vivo*. Exogenous wild-type p53 is also induced in response to genotoxic stress in chemotherapy resistant cancer cells.

In summary, exogenous wild-type p53 gene from rAd-p53 can decrease the expression of PKC, P-gp, and MRP1 in SW480/5-FU (5-FU resistant) and promote apoptosis of tumor cells, which contribute to the reversal of 5-FU resistance *in vivo*. 5-FU can increase the expression of exogenous wild-type p53, thus 5-FU combined with rAd-p53 has a synergistic anticancer effect in colon cancer resistant to 5-FU *in vivo*. Therefore, the DNA-damaging agent 5-FU combined with exogenous wild-type p53 provides a potential therapeutic strategy and can enhance the sensitivity and reduce the toxicity of chemotherapy and improve the clinical efficacy of colon cancer chemotherapy.

**ACKNOWLEDGEMENTS**

A statistical review of the study was performed by Gui-Qin Wang (a biomedical statistician at Nansha Central Hospital, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China).

**COMMENTS**

***Background***

5-fluorouracil (5-FU) is a widely used chemotherapeutic drug in the treatment of advanced CRC: however, response rates are only 10 to 15% due to severe side effects and resistance. Mutations or deletions of p53 can cause cells to become resistant to 5-FU. Therefore, gene replacement therapy for a mutated p53 gene using recombinant adenovirus-mediated p53 (rAd-p53) may overcome 5-FU resistance caused by mutations or deletions of p53. Therefore, rAd-p53 may contribute to the reversal of 5-FU resistance in colon cancer.

***Research frontiers***

Exogenous wild-type p53 from rAd-p53 increased tumor necrosis in human colon cancer SW480 (5-FU responsive) harboring mutant p53, and 5-FU combined with rAd-p53 had a synergistic anticancer effect *in vivo*.

***Innovations and breakthroughs***

This is the first study to evaluate 5-FU combined with rAd-p53 in the treatment of colon cancer SW480/5-FU (5-FU resistant) compared with controls *in vivo*.

***Applications***

This study first showed that exogenous wild-type p53 gene from rAd-p53 can decrease the expression of PKC, P-gp, and MRP1 in colon cancer SW480/5-FU (5-FU resistant) and promote apoptosis of tumor cells, which contribute to the reversal of 5-FU resistance *in vivo*. 5-FU can increase the expression of exogenous wild-type p53, thus 5-FU combined with rAd-p53 had a synergistic anticancer effect in 5-FU resistant colon cancer *in vivo*.

***Terminology***

5-FU increased **t**he expression of exogenous wild-type p53 gene in colon cancer (5-FU resistant) *in vivo*. Exogenous wild-type p53 is also induced in response to genotoxic stress in chemotherapy resistant cancer cells.

***Peer-review***

The authors demonstrated that 5-FU increased **t**he expression of exogenous wild-type p53 gene, and exogenous wild-type p53 is induced in response to genotoxic stress by 5-FU in colon cancer (resistant to 5-FU) *in vivo*. These results

are interesting. Previous studies have established that increased p53 protein in response to genotoxic stress occurs in cancer cells *in vitro*. In this study, the authors showed for the first time that 5-FU combined with rAd-p53 has a synergistic anticancer effect for colon cancer resistant to 5-FU *in vivo*.

**REFERENCES**

1 **Fitzmaurice C**, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. *JAMA Oncol* 2015; **1**: 505-527 [PMID: 26181261 DOI: 10.1001/jamaoncol.2015.0735]

2 **Pardini B**, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, Hemminki K, Vodicka P, Lorenzo Bermejo J. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. *Br J Clin Pharmacol* 2011; **72**: 162-163 [PMID: 21204909 DOI: 10.1111/j.1365-2125.2010.03892.x]

3 **Sui X**, Kong N, Wang X, Fang Y, Hu X, Xu Y, Chen W, Wang K, Li D, Jin W, Lou F, Zheng Y, Hu H, Gong L, Zhou X, Pan H, Han W. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. *Sci Rep* 2014; **4**: 4694 [PMID: 24733045 DOI: 10.1038/srep04694]

4 **Sun XX**, Dai MS, Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. *J Biol Chem* 2007; **282**: 8052-8059 [PMID: 17242401]

5 **Subbarayan PR**, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. *Anticancer Res* 2010; **30**: 1149-1156 [PMID: 20530421]

6 **Huang C**, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. *Cancer Biol Ther* 2009; **8**: 2186-2193 [PMID: 19923910]

7 **Baek JH**, Agarwal ML, Tubbs RR, Vladisavljevic A, Tomita H, Bukowski RM, Milsom JW, Kim JM, Kwak JY. In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer. *J Korean Med Sci* 2004; **19**: 834-841 [PMID: 15608394]

8 **Guan YS**, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma: status quo. *World J Gastroenterol* 2007; **13**: 985-992 [PMID: 17373730 doi: 10.3748/WJG.v13.i7.985]

9 **Inoue H**, Shiraki K, Murata K, Sugimoto K, Kawakita T, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Yamanaka Y, Nakano T. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. *Int J Mol Med* 2004; **14**: 271-275 [PMID: 15254777]

10 **Roth JA**. Adenovirus p53 gene therapy. *Expert Opin Biol Ther* 2006; **6**: 55-61 [PMID: 16370914]

11 **Shimada H**, Shimizu T, Ochiai T, Liu TL, Sashiyama H, Nakamura A, Matsubara H, Gunji Y, Kobayashi S, Tagawa M, Sakiyama S, Hiwasa T. Preclinical study of adenoviral p53 gene therapy for esophageal cancer. *Surg Today* 2001; **31**: 597-604 [PMID: 11495154]

12 **Chen GX**, Zheng LH, Liu SY, He XH. rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. *World J Gastroenterol* 2011; **17**: 4289-4297 [PMID: 22090785 DOI: 10.3748/wjg.v17.i38.4289]

13 **Xie Q**, Liang BL, Wu YH, Zhang J, Chen MW, Liu HY, Gu XF, Xu J. Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. *Gene* 2012; **499**: 303-308 [PMID: 22441128 DOI: 10.1016/j.gene.2012.02.007]

14 **Xie Q**, Yang YM, Wu MYi, Zhang DX, Lei ZX, Zhang J, Xu J, Zhong WD. Detection of the drug resistance of human colon cancer in mice with magnetic resonance diffusion imaging. *Zhongguo Linchuang Yixue Yingxiang Zazhi* 2016; **17**: 355-358, 366

15 **Ahn JY**, Lee JS, Min HY, Lee HY. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. *Oncotarget* 2015; **6**: 32622-32633 [PMID: 26416450 DOI: 10.18632/oncotarget.5327]

16 **Zhang N**, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. *Molecules* 2008; **13**: 1551-1569 [PMID: 18794772]

17 **Kathawala RJ**, Gupta P, Ashby CR, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. *Drug Resist Updat* 2015; **18**: 1-17 [PMID: 25554624 DOI: 10.1016/j.drup.2014.11.002]

18 **Michaelis M**, Rothweiler F, Löschmann N, Sharifi M, Ghafourian T, Cinatl J. Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status. *Oncotarget* 2015; **6**: 17605-17620 [PMID: 25749379]

19 **Balcerczak E**, Panczyk M, Piaskowski S, Pasz-Walczak G, Sałagacka A, Mirowski M. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. *Int J Colorectal Dis* 2010; **25**: 1167-1176 [PMID: 20533057 DOI: 10.1007/s00384-010-0961-2]

20 **He T**, Mo A, Zhang K, Liu L. ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies. *Colorectal Dis* 2013; **15**: 12-18 [PMID: 23279665 DOI: 10.1111/j.1463-1318.2012.02919.x]

21 **Wang X**, Wang C, Qin YW, Yan SK, Gao YR. Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. *Leuk Res* 2007; **31**: 989-994 [PMID: 17067671]

22 **O'Brian CA**, Ward NE, Stewart JR, Chu F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer--an evolving story. *Cancer Metastasis Rev* 2001; **20**: 95-100 [PMID: 11831653]

23 **Zhan M**, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. *J Biol Chem* 2005; **280**: 4825-4833 [PMID: 15563462]

24 **Lo YL**, Liu Y. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides. *PLoS One* 2014; **9**: e90180 [PMID: 24637737 DOI: 10.1371/journal.pone.0090180]

25 **Xue C**, Wang C, Liu Q, Meng Q, Sun H, Huo X, Ma X, Liu Z, Ma X, Peng J, Liu K. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. *Tumour Biol* 2016; Epub ahead of print [PMID: 26733176]

26 **Abdallah HM**, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. *J Adv Res* 2015; **6**: 45-62 [PMID: 25685543 DOI: 10.1016/j.jare.2014.11.008]

27 **Kobori T**, Harada S, Nakamoto K, Tokuyama S. Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs. *J Pharmacol Sci* 2014; **125**: 242-254 [PMID: 24989947]

28 **Gopalakrishna R**, Gundimeda U. Antioxidant regulation of protein kinase C in cancer prevention. *J Nutr* 2002; **132**: 3819S-3823S [PMID: 12468631]

29 **Paulsen CE**, Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. *ACS Chem Biol* 2010; **5**: 47-62 [PMID: 19957967 DOI: 10.1021/cb900258z]

30 **Giorgi C**, Agnoletto C, Baldini C, Bononi A, Bonora M, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Zavan B, Pinton P. Redox control of protein kinase C: cell- and disease-specific aspects. *Antioxid Redox Signal* 2010; **13**: 1051-1085 [PMID: 20136499 DOI: 10.1089/ars.2009.28]

31 **Caino MC**, Meshki J, Kazanietz MG. Hallmarks for senescence in carcinogenesis: novel signaling players. *Apoptosis* 2009; **14**: 392-408 [PMID: 19169823]

32 **Maurya AK**, Vinayak M. Quercetin regresses Dalton's lymphoma growth via suppression of PI3K/AKT signaling leading to upregulation of p53 and decrease in energy metabolism. *Nutr Cancer* 2015; **67**: 354-363 [PMID: 25658812 DOI: 10.1080/01635581.2015.990574]

33 **Vanhaesebroeck B**, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. *Nat Rev Mol Cell Biol* 2010; **11**: 329-341 [PMID: 20379207 DOI: 10.1038/nrm2882]

34 **Maurya AK**, Vinayak M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. *Mol Biol Rep* 2015; **42**: 1419-1429 [PMID: 26311153]

35 **Geering B**, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. *Proc Natl Acad Sci USA* 2007; **104**: 7809-7814 [PMID: 17470792]

36 **Masanek U**, Stammler G, Volm M. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. *J Exp Ther Oncol* ; **2**: 37-41 [PMID: 12415618]

37 **Carson DA**, Lois A. Cancer progression and p53. *Lancet* 1995; **346**: 1009-1011 [PMID: 7475551]

38 **Hodorová I**, Rybárová S, Vecanová J, Solár P, Plank L, Mihalik J. Relation between expression pattern of wild-type p53 and multidrug resistance proteins in human nephroblastomas. *Acta Histochem* 2013; **115**: 273-278 [PMID: 22925562 DOI: 10.1016/j.acthis.2012.08.001]

39 **Bookstein R**, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. *Semin Oncol* 1996; **23**: 66-77 [PMID: 8607033]

40 **Hollstein M**, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science* 1991; **253**: 49-53 [PMID: 1905840]

41 **Levine AJ**, Momand J, Finlay CA. The p53 tumour suppressor gene. *Nature* 1991; **351**: 453-456 [PMID: 2046748]

42 **Spitz FR**, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. *Anticancer Res* ; **16**: 3415-3422 [PMID: 9042200]

43 **Liu YY**, Hill RA, Li YT. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance. *Adv Cancer Res* 2013; **117**: 59-89 [PMID: 23290777 DOI: 10.1016/B978-0-12-394274-6.00003-0]

44 **Grassilli E**, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K, Lavitrano M. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. *Clin Cancer Res* 2013; **19**: 3820-3831 [PMID: 23729362 DOI: 10.1158/1078-0432.CCR-12-3289]

45 **Brosh R**, Rotter V. When mutants gain new powers: news from the mutant p53 field. *Nat Rev Cancer* 2009; **9**: 701-713 [PMID: 19693097 DOI: 10.1038/nrc2693]

46 **Olivier M**, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res* 2006; **12**: 1157-1167 [PMID: 16489069]

47 **Qi X**, Chang Z, Song J, Gao G, Shen Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. *Anticancer Drugs* 2011; **22**: 556-562 [PMID: 21637162 DOI: 10.1097/CAD.0b013e328345b4e7]

48 **García MA**, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, Aránega A. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. *PLoS One* 2011; **6**: e23887 [PMID: 21887339 DOI: 10.1371/journal.pone.0023887]

49 **Levine AJ**. p53, the cellular gatekeeper for growth and division. *Cell* 1997; **88**: 323-331 [PMID: 9039259]

50 **Ko LJ**, Prives C. p53: puzzle and paradigm. *Genes Dev* 1996; **10**: 1054-1072 [PMID: 8654922]

51 **Vogelstein B**, Kinzler KW. p53 function and dysfunction. *Cell* 1992; **70**: 523-526 [PMID: 1505019]

52 **Haupt Y**, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature* 1997; **387**: 296-299 [PMID: 9153395]

53 **Kubbutat MH**, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997; **387**: 299-303 [PMID: 9153396]

54 **Davaadelger B**, Shen H, Maki CG. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. *PLoS One* 2014; **9**: e110844 [PMID: 25380055 DOI: 10.1371/journal.pone.0110844]

55 **Linke SP**, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. *Genes Dev* 1996; **10**: 934-947 [PMID: 8608941]

56 **Mowat MR**. p53 in tumor progression: life, death, and everything. *Adv Cancer Res* 1998; **74**: 25-48 [PMID: 9561266]


57 **Shaw P**, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. *Proc Natl Acad Sci USA* 1992; **89**: 4495-4499 [PMID: 1584781] 58 **Yonish-Rouach E**, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. *Nature* 1991; **352**: 345-347 [PMID: 1852210]

59 **Ju J**, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. *Clin Cancer Res* 2007; **13**: 4245-4251 [PMID: 17634554]


60 **Das R**, Bhattacharya K, Sarkar S, Samanta SK, Pal BC, Mandal C. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma. *Apoptosis* 2014; **19**: 149-164 [PMID: 24052409 DOI: 10.1007/s10495-013-]

61 **Vilgelm AE**, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI. Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. *Mol Cancer Ther* 2010; **9**: 693-705 [PMID: 20197393 DOI: 10.1158/1535-7163.MCT-09-0912]


**P-Reviewer:** Sam MR **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**




A



B




C




D


**Figure 1 Tumor cell apoptosis**. Tumor cell apoptosis at 72 h (× 400) in the control group (a), 5-FU group (b), rAd-p53 group (c) and rAd-p53+5-FU group (d).




A



B



**C**



D

**Figure 2 relative band intensities of p53 expression (a), protein kinase C expression (B), permeability-glycoprotein expression (C) and MRP1 expression (D) in the three experimental groups.**

**Table 1 Tumor apoptosis ratios in experimental groups and control group (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **24 h** | **48 h** | **72 h** | **120 h** | **168 h** |
| Control | 0.25 ± 0.02 | 0.28 ± 0.01 | 0.27 ± 0.02 | 0.29 ± 0.02 | 0.24 ± 0.04 |
| 5-FU | 0.27 ± 0.03 | 0.31 ± 0.03 | 0.31 ± 0.05 | 0.30 ± 0.04 | 0.31 ± 0.02 |
| RAd-p53 | 0.29 ± 0.02 | 0.35 ± 0.03 | 0.43 ± 0.08 | 0.42 ± 0.06 | 0.46 ± 0.06 |
| 5-FU+rAd-p53 | 0.33 ± 0.03 | 0.44 ± 0.08 | 0.58 ± 0.07 | 0.59 ± 0.05 | 0.62 ± 0.07 |
| F | 13.235 | 41.487 | 53.812 | 61.676 | 80.755 |
| *P* | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| *P*  5-FU *vs* Control | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53 *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU  *vs* rAd-p53 | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* 5-FU | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53 *vs* 5-FU | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |

**Table 2 RIOD of p53 expression in experimental groups and control group (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **24 h** | **48 h** | **72 h** | **120 h** | **168 h** |
| Control | 0.099 ± 0.001 | 0.105 ± 0.003 | 0.101 ± 0.007 | 0.105 ± 0.015 | 0.103 ± 0.001 |
| 5-FU | 0.108 ± 0.002 | 0.098 ± 0.028 | 0.096 ± 0.004 | 0.097 ± 0.047 | 0.096 ± 0.033 |
| rAd-p53 | 0.187 ± 0.003 | 0.209 ± 0.014 | 0.627 ± 0.005 | 0.743 ± 0.012 | 0.713 ± 0.005 |
| 5-FU+rAd-p53 | 0.393 ± 0.004 | 0.461 ± 0.002 | 0.691 ± 0.018 | 0.822 ± 0.009 | 0.808 ± 0.027 |
| F | 221.565 | 270.392 | 3983.173 | 9639.595 | 3867.703 |
| *P* | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| *P*  5-FU *vs* Control | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53 *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* rAd-p53 | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* 5-FU | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53 *vs* 5-FU | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |

**Table 3 RIOD of protein kinase C expression in experimental groups and control group (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **24 h** | **48 h** | **72 h** | **120 h** | **168 h** |
| Control | 1.13 ± 0.08 | 1.21 ± 0.06 | 0.99 ± 0.13 | 1.26 ± 0.42 | 1.08 ± 0.20 |
| 5-FU | 0.94 ± 0.21 | 1.12 ± 0.14 | 0.93 ± 0.14 | 1.08 ± 0.52 | 1.04 ± 0.26 |  |
| rAd-p53 | 0.93 ± 0.42 | 0.91 ± 0.23 | 1.07 ± 0.13 | 0.57 ± 0.18 | 0.36 ± 0.09 |
| 5-FU+rAd-p53 | 1.23 ± 0.24 | 0.53 ± 0.09 | 0.45 ± 0.10 | 0.26 ± 0.06 | 0.08 ± 0.01 |
| F | 1.036 | 33.972 | 14.348 | 24.072 | 71.559 |
| *P* | 0.427 | 0.000 | 0.010 | 0.000 | 0.000 |
| *P*  5-FU *vs* Control | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53 *vs* Control | > 0.05 | < 0.05 | > 0.05 | < 0.05 | < 0.05 |
| *P*  rAd/p53+5- FU  *vs* Control | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* rAd-p53 | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* 5-FU | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53 *vs* 5-FU | > 0.05 | < 0.05 | > 0.05 | < 0.05 | < 0.05 |

**Table 4 RIOD of p-gp expression in experimental groups and control group (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **24 h** | **48 h** | **72 h** | **120 h** | **168 h** |
| Control | 1.28 ± 0.20 | 1.32 ± 0.31 | 1.36 ± 0.40 | 1.29 ± 0.43 | 1.30 ± 0.56 |
| 5-FU | 1.17 ± 0.37 | 1.13 ± 0.41 | 1.17 ± 0.39 | 1.27 ± 0.47 | 1.29 ± 0.56 |
| rAd-p53 | 1.12 ± 0.31 | 0.69 ± 0.11 | 0.62 ± 0.02 | 0.36 ± 0.15 | 0.26 ± 0.06 |
| 5-FU+rAd-p53 | 0.86 ± 0.17 | 0.65 ± 0.21 | 0.59 ± 0.25 | 0.31 ± 0.01 | 0.10 ± 0.03 |
| F | 5.670 | 7.301 | 14.645 | 9.844 | 7.971 |
| *P* | 0.022 | 0.011 | 0.001 | 0.005 | 0.009 |
| *P*  5-FU *vs* Control | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53 *vs* Control | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* rAd-p53 | < 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53+5-FU *vs* 5-FU | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53 *vs* 5-FU | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |

**Table 5 RIOD of MRP1 expression in experimental groups and control group (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **24 h** | **48 h** | **72 h** | **120 h** | **168 h** |
| Control | 1.31 ± 0.36 | 1.33 ± 0.08 | 1.09 ± 0.24 | 1.22 ± 0.35 | 1.07 ± 0.22 |
| 5-FU | 1.27 ± 0.10 | 1.31 ± 0.11 | 1.14 ± 0.16 | 1.20 ± 0.31 | 1.13 ± 0.14 |
| rAd-p53 | 0.98 ± 0.09 | 0.74 ± 0.11 | 0.58 ± 0.18 | 0.87 ± 0.31 | 0.31 ± 0.08 |
| 5-FU+rAd-p53 | 0.71 ± 0.17 | 0.62 ± 0.02 | 0.51 ± 0.10 | 0.42 ± 0.08 | 0.13 ± 0.10 |
| F | 6.438 | 123.754 | 20.567 | 15.512 | 36.073 |
| *P* | 0.016 | 0.000 | 0.000 | 0.001 | 0.000 |
| *P*  5-FU *vs* Control | > 0.05 | > 0.05 | > 0.05 | > 0.05 | > 0.05 |
| *P*  rAd-p53 *vs* Control | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* Control | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53+5-FU *vs* rAd-p53 | > 0.05 | < 0.05 | > 0.05 | < 0.05 | > 0.05 |
| *P*  rAd-p53+5-FU *vs* 5-FU | < 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |
| *P*  rAd-p53 *vs* 5-FU | > 0.05 | < 0.05 | < 0.05 | < 0.05 | < 0.05 |